Drugs / Bivalent oral poliovirus vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04579510 Comparator | Feb → Dec 2021 | poliomyelitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent oral poliovirus vaccine | “Bivalent oral poliovirus vaccine (bOPV)” NCT04579510 ↗ |
| Known as | bOPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04579510 ↗ |
| Modality | Vaccine | “Bivalent oral poliovirus vaccine (bOPV; containing Sabin types 1 and 3) is the vaccine of choice for type 1 and type 3 outbreak responses.” PMID 37178706 ↗ May 2023 |
| Route | Oral | “Bivalent oral poliovirus vaccine (bOPV)” NCT04579510 ↗ |